Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma

Ann Oncol. 2010 Jul;21(7):1563-1565. doi: 10.1093/annonc/mdq299.

Authors

M Kodaira¹, S Takahashi², K Takeuchi³, T Yuasa¹, T Saotome¹, J Yonese⁴, I Fukui⁴, K Hatake¹

Affiliations

¹ Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
² Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research. Electronic address: stakahas@jfcr.or.jp.
³ Department of Pathology.
⁴ Department of Urology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.

PMID: 20573851
DOI: 10.1093/annonc/mdq299

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Benzenesulfonates / adverse effects*
Carcinoma, Renal Cell / complications*
Carcinoma, Renal Cell / drug therapy
Carcinoma, Renal Cell / pathology
Erythema Multiforme / chemically induced*
Erythema Multiforme / diagnosis
Erythema Multiforme / drug therapy
Female
Humans
Kidney Neoplasms / complications*
Kidney Neoplasms / drug therapy
Kidney Neoplasms / pathology
Kidney Neoplasms / secondary
Male
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / adverse effects*
Sorafenib
Treatment Outcome

Substances

Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Pyridines
Niacinamide
Sorafenib